1. What Happened?

On August 12, 2025, Celid received a favorable ruling in a trademark infringement lawsuit filed by GreenGenius. The court dismissed the injunction request, ruling in favor of Celid and assigning court costs to GreenGenius.

2. Why Does It Matter?

This ruling removes legal uncertainty surrounding Celid. It prevents unnecessary legal expenses and strengthens the company’s image and credibility. Furthermore, it secures Celid’s right to use its trademark, ensuring operational stability.

3. What is Celid?

Celid is a biopharmaceutical company focused on developing cancer immunotherapy vaccines and a COVID-19 vaccine. Its key pipelines include BVAC-C for cervical cancer, BVAC-E6E7 for head and neck cancer, and AdCLD-CoV19-1 OMI for COVID-19. Currently, the company is heavily investing in R&D while generating ancillary revenue through its e-commerce business.

  • Core Business: Biopharmaceutical development (cancer immunotherapy vaccines, COVID-19 vaccine)
  • Financials: Operating losses due to R&D investment (as of Q1 2025)
  • Growth Drivers: Promising drug pipelines, CMO/CDMO business expansion

4. What’s Next?

While this legal win could positively impact the stock price in the short term, the long-term trajectory depends on the success of Celid’s key pipeline development. Investors should monitor clinical trial results, regulatory approvals, and funding plans.

5. What Should Investors Do?

  • Short-term investors: Invest cautiously, considering potential price volatility.
  • Long-term investors: Continuously monitor drug development progress and financial stability.